Isis will provide Biogazelle with access to its antisense platform for the large-scale validation of therapeutic lncRNA targets from Biogazelle's target identification pipeline.

The accreditation is for the Belgian firm's mRNA, miRNA, and long non-coding RNA expression services.

NEW YORK (GenomeWeb) — Biogazelle said today that it has received a €2 million ($2.5 million) investment from Qbic Arkiv Fund, Foundation Majoie, and SOFI (Spin-Off Financing Instrument).

Core Life Sciences has signed a deal with Biogazelle that lets that company distribute qbase+, Core's software for analyzing qPCR data, in California.

Core Life Sciences said today that it has partnered with Belgium's Biogazelle to distribute its qbase+ qPCR software in California.

NEW YORK (GenomeWeb News) – Core Life Sciences announced this week that it and Biogazelle have reached an agreement to distribute Biogazelle's qbase+ software in California.

Belgium's Flanders Institute for Biotechnology, VIB, has licensed Biogazelle’s qbase+ software to support its real time PCR-based research projects.

BITS, the bioinformatics training and service facility of Belgium's Vlaams Instituut voor Biotechnologie, or VIB, will use Biogazelle's qbase+ software for PCR analysis, Biogazelle said this week.

Bio-Rad this week introduced qPCR assays and panels that have been wet-lab validated to meet the minimum information for publication of quantitative real-time PCR experiments, or MIQE, guidelines.

University of Rochester Medical Center said this week that Hulin Wu, a professor of biostatistics and computational biology, will serve as the founding director of its newly established Center for Integrative Bioinformatics and Experimental Mathematics.


An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.